EFGR inhibitor, preparation method therefor and application thereof

A compound of formula (IIb) or formula (IIc), a stereoisomer or pharmaceutically acceptable salt thereof:

• wherein ring A, together with —(R4)n, forms the following structure:
• wherein each R is independently hydrogen;
• each R1 s independently vinyl optionally further substituted with one or more R1 substituents selected from the group consisting of deuterium, fluoro, cyano, methyl, and dimethylaminomethyl;
• each R2 is independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, bromo, C1-4 alkyl, C2-4 alkynyl, 3-6 membered heterocyclyl, —O—R9, and —NR12R13, the above R2 groups independently optionally further substituted with one or more R2 substituents selected from the group consisting of deuterium, fluoro, chloro, bromo, cyano, C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, ═O, —O—R9, and —NR12R13, the above one or more R2 substituent groups independently optionally further substituted with one or more R2 further substituents selected from the group consisting of deuterium, fluoro, chloro, bromo, cyano, C1-4 alkyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, ═O, —O—R9, and —NR12R13;
• each R3 is independently selected from the group consisting of hydrogen;
• each R4 is independently selected from the group consisting of hydrogen, fluoro, chloro and bromo;
• each R9 is independently selected from the group consisting of hydrogen, deuterium, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-8 aryl, and 5-8 membered heteroaryl, the above R9 groups independently optionally further substituted with one or more R9 substituents selected from the group consisting of deuterium, halogen, hydroxy, oxo, cyano, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C6-8 aryl, C6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, and —NR12R13;
• each of R12 and R13 is independently selected from the group consisting of hydrogen, deuterium, hydroxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl, amino, monoC1-4 alkylamino, diC1-4 alkylamino, and C1-4 alkanoyl, each of the above R12/R13 groups independently optionally further substituted with one or more R12/R13 substituents selected from the group consisting of deuterium, halogen, hydroxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C1-4 alkoxy, C3-6 cycloalkyl, C3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C6-8 aryl, C6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, monoC1-4 alkylamino, diC1-4 alkylamino, and C1-4 alkanoyl,
• or, R12 and R13, together with the nitrogen atom to which they are directly attached, form a 4-8 membered heterocyclyl, or 5-8 membered heteroaryl, the 4-8 membered heterocyclyl or 5-8 membered heteroaryl optionally further substituted with one or more R12/R13 substituents selected from the group consisting of deuterium, halogen, hydroxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C1-4 alkoxy, C3-6 cycloalkyl, C3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C6-8 aryl, C6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, monoC1-4 alkylamino, diC1-4 alkylamino, and C1-4 alkanoyl.